摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,4-Bis(phenylmethyl)morpholine | 136423-20-6

中文名称
——
中文别名
——
英文名称
2,4-Bis(phenylmethyl)morpholine
英文别名
2,4-dibenzylmorpholine
2,4-Bis(phenylmethyl)morpholine化学式
CAS
136423-20-6
化学式
C18H21NO
mdl
——
分子量
267.371
InChiKey
GTUHMBJYOFXILZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    12.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    吗啉苯甲醇D(+)-10-樟脑磺酸 、 dichloro[1-(2,4,6-trimethylbenzyl)-3-(2-(1,3-dioxane-2-yl)ethyl)benzimidazole-2-ylidene](p-cymene)ruthenium(II) 作用下, 以 甲苯 为溶剂, 反应 16.0h, 生成 4-(苯基甲基)吗啉2,4-Bis(phenylmethyl)morpholine
    参考文献:
    名称:
    带有N-杂环卡宾的Ru(II)配合物催化环胺与醇的烷基化
    摘要:
    本文包括2-(1,3-二恶烷-2-基)乙基取代的苯并咪唑取代的N-杂环卡宾前体及其钌配合物的合成。合成的化合物通过元素分析和NMR光谱进行表征。所有配合物均已在吡咯烷和吗啉与醇的烷基化反应中进行了测试,在该反应中显示出出色的活性。
    DOI:
    10.1016/j.tet.2017.09.027
点击查看最新优质反应信息

文献信息

  • Alkylation of cyclic amines with alcohols catalyzed by Ru(II) complexes bearing N -Heterocyclic carbenes
    作者:Öznur Doğan Ulu、Nevin Gürbüz、İsmail Özdemir
    DOI:10.1016/j.tet.2017.09.027
    日期:2018.2
    includes the synthesis of 2-(1,3-dioxane-2-yl)ethyl substituted benzimidazole substituted N-heterocyclic carbenes precursors and their ruthenium complexes. Synthesized compounds were characterized by elemental analysis and NMR spectroscopy. All complexes have been tested in the alkylation of pyrrolidine and morpholine with alcohols, showing an excellent activity in this reaction.
    本文包括2-(1,3-二恶烷-2-基)乙基取代的苯并咪唑取代的N-杂环卡宾前体及其钌配合物的合成。合成的化合物通过元素分析和NMR光谱进行表征。所有配合物均已在吡咯烷和吗啉与醇的烷基化反应中进行了测试,在该反应中显示出出色的活性。
  • Hydrazone complexes of ruthenium(II): Synthesis, crystal structures and catalytic applications in N-alkylation reactions
    作者:Kaliyappan Murugan、Subbarayan Vijayapritha、Muthukumaran Nirmala、Periasamy Viswanathamurthi、Karuppannan Natarajan
    DOI:10.1016/j.jorganchem.2020.121411
    日期:2020.9
    ESI-MS spectral methods. Further, structures of two of the complexes have been determined by single crystal X-ray diffraction technique which revealed a pseudo octahedral geometry with the coordination of the quinoline nitrogen and quinoline oxygen atoms of the ligand. All the new complexes have been employed as efficient catalysts in N-alkylation reactions for the synthesis of tertiary amines by the coupling
    一系列新的通式为[RuH(CO)(EPh 3)2 L](1-6)的8-羟基喹啉-2-羧醛的Ru(II)配合物(E = P或As,L = N '-(((8-羟基喹啉-2-基)亚甲基)噻吩-2-碳酰肼(HQ-THy),N'-(((8-羟基喹啉-2-基)亚甲基)异烟酰肼(HQ-IHy),N'-已经合成了((8-羟基喹啉-2-基)亚甲基)苯甲酰肼(HQ-BHy)。它们已通过元素分析,IR,NMR(1 H,13 C和31P)和ESI-MS光谱方法。此外,已经通过单晶X射线衍射技术确定了两种配合物的结构,该技术揭示了配体的喹啉氮和喹啉氧原子配位的伪八面体几何形状。通过将仲胺与芳族伯醇在低催化剂负载下以最大收率偶联,所有新的络合物已被用作N-烷基化反应中合成叔胺的有效催化剂。另外,已经充分研究了取代基对配体,不同溶剂以及碱和催化剂负载量对配合物催化活性的影响。综合大楼1业已发现,AlO3是醇与胺的N-烷
  • Novel Compounds
    申请人:Fish Paul Vincent
    公开号:US20080161309A1
    公开(公告)日:2008-07-03
    The present invention provides compounds of Formula I wherein R 1 , R 2 , R 3 , and n have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of conditions including urinary disorders, pain, premature ejaculation, ADHD and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
    本发明提供了公式I的化合物,其中R1,R2,R3和n具有规范中定义的任何值,以及其药学上可接受的盐,可用作治疗包括尿路疾病、疼痛、早泄、注意力缺陷多动障碍和纤维肌痛等疾病的药物。还提供了包含一种或多种公式I化合物的制药组合物。
  • Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof
    申请人:Fish Paul Vincent
    公开号:US20100137316A1
    公开(公告)日:2010-06-03
    The present invention provides compounds of Formula I wherein R 1 , R 2 , R 3 , and n have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of conditions including urinary disorders, pain, premature ejaculation, ADHD and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
    本发明提供了公式I的化合物,其中R1、R2、R3和n的任何值均在规范中定义,并且其药物可接受的盐,在治疗包括泌尿系统疾病、疼痛、早泄、注意力缺陷多动障碍和纤维肌痛等病症的药物中有用。还提供了包含一个或多个公式I化合物的制药组合物。
  • N-Alkylation and N,C-Dialkylation of Amines with Alcohols in the Presence of Ruthenium Catalysts with Chelating N-Heterocyclic Carbene Ligands
    作者:Zeynel Şahin、Nevin Gürbüz、İsmail Özdemir、Onur Şahin、Orhan Büyükgüngör、Mathieu Achard、Christian Bruneau
    DOI:10.1021/om501066n
    日期:2015.6.8
    A series of new benzimidazolium salts and ruthenium(II) complexes containing chelating N-heterocyclic carbenes (NHCs) functionalized with a benzylic group and an acetal group were prepared. All of the synthesized compounds were characterized by elemental analysis and NMR spectroscopy, and the molecular structures of 2c and 2d were determined by X-ray crystallography. All of the,complexes were tested in the alkylation of cyclic amine derivatives with alcohols and showed excellent activity in this reaction. Cyclic amines were alkylated with primary and heteroaromatic alcohols. The Ru-NHC Complexes also catalyzed N,C3-dialkylation of cyclic amines.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐